92 related articles for article (PubMed ID: 12514866)
21. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
23. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
24. Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
Gupta S
Nat Clin Pract Oncol; 2005 Feb; 2(2):80-1. PubMed ID: 16264879
[No Abstract] [Full Text] [Related]
25. [A case of left breast cancer resulting in complete response by primary systemic therapy].
Fukuda T; Watanabe T; Kawahara M; Kodama H; Kikuchi S; Suzuki H
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1497-500. PubMed ID: 17876155
[TBL] [Abstract][Full Text] [Related]
26. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
27. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
28. [A case of advanced breast cancer leading to DIC after chemotherapy].
Ishizuka S; Morikawa T; Yoshida K; Nobuhisa T; Endo Y; Watanabe T; Matsumoto Y; Doi Y; Yamada T; Kai K; Nakashima A; Nagahiro I; Sato S; Nakashima A; Nabeyama A
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1845-8. PubMed ID: 18030021
[TBL] [Abstract][Full Text] [Related]
29. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P; Roché H; Bonneterre J; Veyret C; Lortholary A; Monnier A; Fumoleau P; Fargeot P; Namer M; Chollet P; Goudier MJ; Audhuy B; Simon H; Montcuquet P; Eymard JC; Walter S; Clavère P; Guastalla JP;
Br J Cancer; 2007 Jun; 96(11):1633-8. PubMed ID: 17505516
[TBL] [Abstract][Full Text] [Related]
30. High-dose adjuvant chemotherapy for patients with high-risk breast cancer: efficacy is still an open question.
Clin Breast Cancer; 2000 Oct; 1(3):191-2. PubMed ID: 11899643
[No Abstract] [Full Text] [Related]
31. [Taxol based chemotherapy in the treatment of advanced gastric cancer].
Li Y; Wu XQ; Cui HJ; Tan HY
Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):562-4. PubMed ID: 15555290
[TBL] [Abstract][Full Text] [Related]
32. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Fornier MN; Seidman AD; Lake D; D'Andrea G; Bromberg J; Robson M; Van Poznak C; Panageas KS; Atienza M; Norton L; Hudis C
Clin Cancer Res; 2007 Jan; 13(1):223-7. PubMed ID: 17200358
[TBL] [Abstract][Full Text] [Related]
33. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study.
Gebbia V; Blasi L; Borsellino N; Caruso M; Leonardi V; Agostara B; Valenza R
Anticancer Res; 2003; 23(1B):765-71. PubMed ID: 12680181
[TBL] [Abstract][Full Text] [Related]
35. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Green MC; Buzdar AU; Smith T; Ibrahim NK; Valero V; Rosales MF; Cristofanilli M; Booser DJ; Pusztai L; Rivera E; Theriault RL; Carter C; Frye D; Hunt KK; Symmans WF; Strom EA; Sahin AA; Sikov W; Hortobagyi GN
J Clin Oncol; 2005 Sep; 23(25):5983-92. PubMed ID: 16087943
[TBL] [Abstract][Full Text] [Related]
36. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Conte PF; Guarneri V; Bruzzi P; Prochilo T; Salvadori B; Bolognesi A; Aldrighetti D; Venturini M; Rosso R; Mammoliti S; Carnino F; Giannessi P; Costantini M; Moyano A; Baldini E;
Cancer; 2004 Aug; 101(4):704-12. PubMed ID: 15305399
[TBL] [Abstract][Full Text] [Related]
37. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
38. Use of dose-dense chemotherapy in the management of breast cancer.
Norton L
Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
[No Abstract] [Full Text] [Related]
39. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials.
Anderson JR; Cain KC; Gelber RD; Gelman RS
Cancer Treat Rep; 1985 Oct; 69(10):1139-46. PubMed ID: 3899355
[No Abstract] [Full Text] [Related]
40. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide for metastatic breast cancer.
Atkins CD
J Clin Oncol; 2001 Jul; 19(14):3441-2. PubMed ID: 11454896
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
